Boston Scientific Corporation $BSX Stake Lifted by Savvy Advisors Inc.

Savvy Advisors Inc. lifted its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 56.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 22,361 shares of the medical equipment provider’s stock after acquiring an additional 8,024 shares during the quarter. Savvy Advisors Inc.’s holdings in Boston Scientific were worth $2,132,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in shares of Boston Scientific by 0.8% in the third quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider’s stock valued at $13,497,294,000 after buying an additional 1,115,337 shares during the period. State Street Corp grew its holdings in Boston Scientific by 1.1% during the second quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock worth $7,002,258,000 after acquiring an additional 713,379 shares during the period. Synergy Asset Management LLC raised its position in Boston Scientific by 3,493.0% in the third quarter. Synergy Asset Management LLC now owns 493,323 shares of the medical equipment provider’s stock worth $48,297,000 after acquiring an additional 479,593 shares in the last quarter. Gladstone Institutional Advisory LLC raised its position in Boston Scientific by 39.5% in the third quarter. Gladstone Institutional Advisory LLC now owns 51,884 shares of the medical equipment provider’s stock worth $5,065,000 after acquiring an additional 14,700 shares in the last quarter. Finally, Kepler Cheuvreux Suisse SA acquired a new stake in Boston Scientific in the 3rd quarter valued at about $26,955,000. Institutional investors own 89.07% of the company’s stock.

Insider Activity at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.50% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities analysts have recently issued reports on BSX shares. Raymond James Financial reaffirmed an “outperform” rating and issued a $88.00 price objective (down from $97.00) on shares of Boston Scientific in a research note on Monday, March 30th. Wells Fargo & Company cut their target price on shares of Boston Scientific from $125.00 to $94.00 and set an “overweight” rating for the company in a research note on Thursday, February 5th. Barclays decreased their price target on shares of Boston Scientific from $136.00 to $124.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 3rd. Mizuho dropped their price target on Boston Scientific from $140.00 to $115.00 and set an “outperform” rating on the stock in a report on Thursday, February 5th. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of Boston Scientific in a research report on Monday, March 16th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, Boston Scientific presently has an average rating of “Moderate Buy” and a consensus target price of $104.36.

Boston Scientific Stock Down 0.1%

BSX stock opened at $62.73 on Monday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. The firm has a market capitalization of $93.23 billion, a P/E ratio of 32.34, a P/E/G ratio of 0.97 and a beta of 0.78. Boston Scientific Corporation has a 52-week low of $61.24 and a 52-week high of $109.50. The company’s 50 day simple moving average is $74.61 and its 200-day simple moving average is $89.26.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The firm had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.29 billion. During the same quarter last year, the business posted $0.70 EPS. The company’s revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, equities research analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current year.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.